Abbott Laboratories (ABT) To Go Ex-Dividend on October 15th

Abbott Laboratories (NYSE:ABT) announced a quarterly dividend on Friday, September 19th, RTT News reports. Stockholders of record on Wednesday, October 15th will be paid a dividend of 0.59 per share by the healthcare product maker on Monday, November 17th. This represents a c) dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th.

Abbott Laboratories has a payout ratio of 41.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Abbott Laboratories to earn $5.73 per share next year, which means the company should continue to be able to cover its $2.36 annual dividend with an expected future payout ratio of 41.2%.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $132.30 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock has a market cap of $230.26 billion, a PE ratio of 16.58, a PEG ratio of 2.51 and a beta of 0.69. The company’s fifty day moving average is $132.54 and its 200 day moving average is $131.60. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by corporate insiders.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the stock. IMG Wealth Management Inc. increased its holdings in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares in the last quarter. Hughes Financial Services LLC bought a new position in Abbott Laboratories in the 1st quarter worth about $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the 1st quarter valued at about $30,000. Finally, JCIC Asset Management Inc. purchased a new position in Abbott Laboratories in the first quarter worth about $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.